Levodopa

dopamine receptor D2 ; Homo sapiens







26 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34125397 Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models. 2021 Dec 1
2 30353564 The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease. 2019 Feb 4
3 27779245 Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease. 2018 Jan 3
4 28253352 Dopamine D2 receptor and β-arrestin 2 mediate Amyloid-β elevation induced by anti-parkinson's disease drugs, levodopa and piribedil, in neuronal cells. 2017 1
5 28687316 Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under α-synuclein-induced toxicity. 2017 Sep 1 3
6 28927418 A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease. 2017 Sep 19 1
7 25274160 Central pharmacokinetics of levodopa: Lessons from imaging studies. 2015 Jan 1
8 25505120 Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates. 2015 Mar 1 1
9 24705818 Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys. 2014 Dec 2
10 23439215 Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease. 2013 May 15 5
11 23613810 Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa. 2013 1
12 22751085 Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. 2012 Jul-Aug 1
13 23171335 DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. 2012 Nov 2
14 23223310 Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. 2012 Dec 5 2
15 20026151 Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. 2010 Apr 16 1
16 12796525 L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. 2003 Jun 10 1
17 14683704 Systemic sulpiride modulates striatal blood flow: relationships to spatial working memory and planning. 2003 Dec 1
18 11844900 Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. 2002 2
19 11166288 Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. 2001 Feb 2 1
20 10534246 Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. 1999 Oct 22 2
21 9483165 Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. 1998 1
22 8915594 Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. 1996 Nov 1
23 7884499 Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. 1995 Mar 1
24 7984527 [Progressive supranuclear paralysis. Quantification of dopamine D2 receptors using radionuclide tomography]. 1994 Sep 24 1
25 7901395 Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. 1993 Oct 1
26 2950731 Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy. 1987 1